DK1565160T3 - Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf - Google Patents

Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf

Info

Publication number
DK1565160T3
DK1565160T3 DK03779793.3T DK03779793T DK1565160T3 DK 1565160 T3 DK1565160 T3 DK 1565160T3 DK 03779793 T DK03779793 T DK 03779793T DK 1565160 T3 DK1565160 T3 DK 1565160T3
Authority
DK
Denmark
Prior art keywords
administration
preparation
sustained release
pharmaceutically active
active peptides
Prior art date
Application number
DK03779793.3T
Other languages
English (en)
Inventor
Horst Bauer
Thomas Reissmann
Peter Romeis
Berthold Roessler
Original Assignee
Terna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10245525A external-priority patent/DE10245525A1/de
Application filed by Terna Zentaris Gmbh filed Critical Terna Zentaris Gmbh
Application granted granted Critical
Publication of DK1565160T3 publication Critical patent/DK1565160T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
DK03779793.3T 2002-09-27 2003-09-26 Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf DK1565160T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41422502P 2002-09-27 2002-09-27
DE10245525A DE10245525A1 (de) 2002-09-27 2002-09-27 Darreichungsform für pharmazeutisch aktive Peptide mit anhaltender Wirkstofffreigabe (sustained release) und Verfahren zu deren Herstellung
DE10320051 2003-04-26
PCT/EP2003/010732 WO2004030650A2 (de) 2002-09-27 2003-09-26 Darreichungsform für pharmazeutisch aktive peptide mit anhaltender wirkstofffreigabe (sustained release) und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
DK1565160T3 true DK1565160T3 (da) 2014-04-28

Family

ID=43646377

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03779793.3T DK1565160T3 (da) 2002-09-27 2003-09-26 Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf

Country Status (23)

Country Link
US (1) US7884071B2 (da)
EP (1) EP1565160B1 (da)
JP (1) JP4898118B2 (da)
KR (1) KR100633280B1 (da)
CN (1) CN100509053C (da)
AU (1) AU2003287950B2 (da)
BR (1) BRPI0314546B8 (da)
CA (1) CA2507524C (da)
DK (1) DK1565160T3 (da)
ES (1) ES2457019T3 (da)
HK (1) HK1081855A1 (da)
HR (1) HRP20050371B1 (da)
IL (1) IL167415A (da)
IS (1) IS7750A (da)
ME (1) ME00509B (da)
MX (1) MXPA05003318A (da)
NO (1) NO338309B1 (da)
NZ (1) NZ538928A (da)
PL (1) PL208073B1 (da)
RS (2) RS52966B (da)
RU (1) RU2333743C2 (da)
WO (1) WO2004030650A2 (da)
ZA (1) ZA200502150B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2705854A1 (en) * 2006-01-05 2014-03-12 Novartis AG Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20070219811A1 (en) * 2006-03-16 2007-09-20 Kim John S Method for using an internet-based CRM application to create an on-line leads marketplace
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
ES2447516T3 (es) * 2006-12-21 2014-03-12 Stryker Corporation Formulaciones de liberación sostenida que comprenden cristales BMP-7
KR101749310B1 (ko) 2008-01-24 2017-06-21 에스퍼란스 파마슈티컬스, 인코포레이티드 용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
US8324347B2 (en) * 2009-02-24 2012-12-04 Institute For Systems Biology Methods of using halogenated peptides as internal standards for liquid chromatography-mass spectrometry
TWI508734B (zh) * 2009-05-01 2015-11-21 Ferring Int Ct Sa 用於前列腺癌之治療的組成物
EP2523653B1 (en) 2010-01-13 2018-04-11 Ipsen Pharma S.A.S. Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
CA3228586A1 (en) 2012-06-01 2013-12-05 Ferring B.V. Manufacture of degarelix
ITMI20121638A1 (it) * 2012-10-02 2014-04-03 Marco Sbracia Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate
CN105121472A (zh) 2012-10-30 2015-12-02 埃斯佩兰斯医药公司 抗体/药物缀合物及其使用方法
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
WO2018144603A1 (en) * 2017-01-31 2018-08-09 Veru Inc. COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GANADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
WO2019066199A1 (ko) 2017-09-27 2019-04-04 주식회사 제이피바이오지 지속형 팔미트산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물
KR102408887B1 (ko) * 2018-01-31 2022-06-14 저장 산후아 클라이메이트 앤드 어플라이언스 컨트롤스 그룹 컴퍼니 리미티드 전기 밸브

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
GB9108634D0 (en) 1991-04-23 1991-06-12 Ciba Geigy Pharmaceutical compositions
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
DE4305225A1 (de) 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5942493A (en) * 1995-11-28 1999-08-24 Asta Medica Aktiengesellschaft LH-RH antagonists having improved action
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
EP1007080B1 (en) * 1996-08-30 2007-04-18 Peptech Limited Formulation for the sustained release of peptide agonists and analogues of GnRH
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
CA2336879C (en) * 1998-07-20 2010-06-01 Peptech Limited Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US7005418B1 (en) * 1999-09-23 2006-02-28 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
US6635739B2 (en) * 1999-10-15 2003-10-21 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
HRP20050371A2 (en) 2005-06-30
ZA200502150B (en) 2005-11-30
JP2006505538A (ja) 2006-02-16
ME00509B (me) 2011-10-10
RU2333743C2 (ru) 2008-09-20
HK1081855A1 (en) 2006-05-26
ES2457019T3 (es) 2014-04-24
BRPI0314546A8 (pt) 2015-12-15
BR0314546A (pt) 2005-08-09
US20050282731A1 (en) 2005-12-22
PL376446A1 (en) 2005-12-27
IL167415A (en) 2014-05-28
BRPI0314546B1 (pt) 2020-04-07
CN100509053C (zh) 2009-07-08
RU2005113163A (ru) 2005-10-10
JP4898118B2 (ja) 2012-03-14
MXPA05003318A (es) 2005-09-12
NO20052041L (no) 2005-06-10
BRPI0314546B8 (pt) 2021-05-25
CN1684703A (zh) 2005-10-19
PL208073B1 (pl) 2011-03-31
KR100633280B1 (ko) 2006-10-16
KR20050084829A (ko) 2005-08-29
WO2004030650A3 (de) 2004-07-15
EP1565160B1 (de) 2014-01-22
CA2507524A1 (en) 2004-04-15
EP1565160A2 (de) 2005-08-24
HRP20050371B1 (hr) 2014-09-26
US7884071B2 (en) 2011-02-08
RS20050247A (en) 2007-06-04
RS52966B (en) 2014-02-28
NZ538928A (en) 2006-10-27
IS7750A (is) 2005-03-17
CA2507524C (en) 2012-12-11
AU2003287950B2 (en) 2009-01-29
NO338309B1 (no) 2016-08-08
WO2004030650A2 (de) 2004-04-15
AU2003287950A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
DK1565160T3 (da) Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf
NO20025552L (no) Mikrosf¶rer med forsinket frigjöring for injeserbar administrering og fremgangsmåte til fremstilling derav
NO20050948L (no) Preparater med langvarig frigivelse omfattende lamotrigin
EP1365747A4 (en) PHARMACEUTICAL PRESENTATION OF ORAL PEPTIDE ADMINISTERED AND METHOD OF PRODUCTION
NO2013007I1 (no) Dapagliflozin og farmasøytisk akseptable salter derav
NO2010006I1 (no) Saksagliptin og farmasytisk akseptable salter derav inklusive saksagliptin hydroklorid
DK1480622T3 (da) Farmaceutiske, granulære immediate release-præparater og en kontinuert fremgangsmåde til fremstilling deraf
NO2011021I2 (no) Apixaban og farmasøytiske akseptable salter derav
EP1477119A4 (en) METHOD OF DRUG DELIVERY
DK1562573T3 (da) Farmaceutiske pellets omfattende tamsulosin og en fremgangsmåde til fremstilling deraf
PL1940364T3 (pl) Preparat pirfenidonu i farmaceutycznie dopuszczalnych zaróbek w postaci kapsułki
IL166772A0 (en) Pharmaceuticals formulations and methods for modified release of statin drugs
HK1066459A1 (en) Pharmaceutical dosage form and method of making
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
IL162666A0 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
HUP0302050A3 (en) Pharmaceutical form of administration for peptides, method for its production and use
AU2003293593A8 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
IL164903A0 (en) Processes for preparation of polymorphic form II of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
NO20021094L (no) Profylaktiske og terapeutiske medikamenter for oftalmologiske sykdommer
EP1575987A4 (en) CONJUGATES OF MEMBRANE TRANSLOCATION AGENTS AND PHARMACEUTICAL ACTION AGENTS
IS7266A (is) Lyfjaform sem innihalda sýru-óþolin virk efni og aðferðir til tilreiðslu þeirra
ATE451912T1 (de) Arzneistoffhaltiger kaugummi, dessen herstellungsverfahren und so erhaltene tablette
NO20044342L (no) Androgent farmasoytisk preparat og fremgangsmate for behandling av depresjon
AU2003260239A1 (en) Solid dosage forms for rapid dissolution of poorly soluble drugs
HK1044719B (zh) 持續釋放的藥學活性肽鹽及其生產